Z
Zhongxing Jiang
Researcher at Zhengzhou University
Publications - 89
Citations - 834
Zhongxing Jiang is an academic researcher from Zhengzhou University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 11, co-authored 49 publications receiving 254 citations.
Papers
More filters
Journal ArticleDOI
Targeting CD47 for cancer immunotherapy.
TL;DR: In this article, the authors summarized the CD47-related clinical research and analyzed the research trend both in the USA and in China for cancer immunotherapy in solid tumors (ST) and hematological malignancies.
Journal ArticleDOI
Circ_0009910 promotes imatinib resistance through ULK1-induced autophagy by sponging miR-34a-5p in chronic myeloid leukemia
TL;DR: Circ_0009910 accelerated imatinib-resistance in CML cells by modulating ULK1-induced autophagy via targeting miR-34a-5p, providing a potential target in imatinIB resistance of CML.
Journal ArticleDOI
Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia.
Jifeng Yu,Yingmei Li,Tao Li,Yafei Li,Haizhou Xing,Hui Sun,Ling Sun,Dingming Wan,Yan-Fang Liu,Xinsheng Xie,Zhongxing Jiang +10 more
TL;DR: AML patients with fewer or no gene mutations had a better chance of achieving CR when treated with IA and DA regimen induction chemotherapy and the response of newly diagnosed AML patients to standard DA or IA induction chemotherapy was analyzed.
Journal ArticleDOI
Advances in targeted therapy for acute myeloid leukemia
TL;DR: Since Midostaurin, a FLT3 inhibitor, was first approved by US FDA in 2017 as the first gene mutation-targeted therapeutic agent, an array of new gene mutation -targeted agents are now available for AML treatment.
Journal ArticleDOI
Clinical implications of recurrent gene mutations in acute myeloid leukemia.
TL;DR: This review summarized the recent development on the gene mutation in patients with AML and identified an enormous diversity of genetic mutations.